A consortium of new and previous backers led by Life Sciences Partners (LSP) has invested $38.5m in France-based DNA Script, a manufacturer of synthetic DNA.
GPs will sell their entire interest in the share capital of Altran for €14 per share
Vendors Zwanenberg and René Hochstenbach will retain minority stakes following the acquisition
Fund will target seed and series-A opportunities in technology sectors across Europe
Company plans to increase its revenues and to double its network of clinics by 2021